Sandra Jesse - Haemonetics Vice President Chief Legal Officer

HAE Stock  USD 84.09  2.45  3.00%   

President

Ms. Sandra Jesse is Executive Vice President, Chief Legal Officer of the company. She joined Haemonetics as Vice President, Chief Legal Officer in September 2011, and is responsible for the companys Legal, Compliance and Corporationrationrate Audit and Controls groups. Ms. Jesse was previously the Executive Vice President and Chief Legal Officer of Blue Cross Blue Shield of Massachusetts, a Partner in the Boston law firm of Choate, Hall and Stewart, and Press Secretary for a United States Congressman, Lee Hamilton. since 2016.
Age 62
Tenure 8 years
Address 125 Summer Street, Boston, MA, United States, 02110
Phone781 848 7100
Webhttps://www.haemonetics.com
Jesse is a former President of the Boston Bar Foundation.

Haemonetics Management Efficiency

The company has Return on Asset of 0.0612 % which means that on every $100 spent on assets, it made $0.0612 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1472 %, implying that it generated $0.1472 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 929.4 M, whereas Other Current Assets are forecasted to decline to about 35.8 M.
The company has 765.89 M in debt with debt to equity (D/E) ratio of 1.12, which is OK given its current industry classification. Haemonetics has a current ratio of 2.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Haemonetics until it has trouble settling it off, either with new capital or with free cash flow. So, Haemonetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Haemonetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Haemonetics to invest in growth at high rates of return. When we think about Haemonetics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Lance BerberianLaboratory
61
Kristen LauriaCigna Corp
51
Stephen AndersonLaboratory
N/A
Kevin SmithMednax Inc
N/A
Christopher MBACigna Corp
N/A
AmirAli TalasazGuardant Health
44
Mark BoxerCigna Corp
59
ALAN MUNEYCigna Corp
63
Michael PhillipsCigna Corp
N/A
Matthew MandersCigna Corp
58
Brian EvankoCigna Corp
47
Sandra VaartLaboratory
64
Edwin DetrickCigna Corp
N/A
John MurabitoCigna Corp
62
Brian CaveneyLaboratory
47
Scott FrommerLaboratory
N/A
Charles LynchMednax Inc
N/A
Matt PerlbergCigna Corp
N/A
JD MDLaboratory
50
Nicole JonesCigna Corp
53
Greg AllenCigna Corp
N/A
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people. Haemonetics (HAE) is traded on New York Stock Exchange in USA. It is located in 125 Summer Street, Boston, MA, United States, 02110 and employs 3,034 people. Haemonetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Haemonetics Leadership Team

Elected by the shareholders, the Haemonetics' board of directors comprises two types of representatives: Haemonetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haemonetics. The board's role is to monitor Haemonetics' management team and ensure that shareholders' interests are well served. Haemonetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haemonetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Susan Hanlon, Chief Accounting Officer and VP of Fin.
Stewart Strong, Pres Hospital
Rajeev Varma, Senior Development
William Burke, Chief Financial Officer, Executive Vice President
Olga Guyette, Director Relations
Carla Burigatto, VP Communications
Laurie Miller, Senior Officer
Anthony Gazikas, CIO and VP
Susan Foote, Independent Director
David Helsel, Executive Vice President - Global Manufacturing
Seyed Mirsaid, Executive Vice President, Chief Technology Officer
Ronald Gelbman, Interim CEO, Lead Director, Chairman of Governance and Compliance Committee and Member of Audit Committee
Robert Abernathy, Independent Director
Neil Ryding, Executive Vice President Global Operations
Ellen Zane, Non-Executive Independent Chairman of the Board
David Wilson, President - Plasma Business Unit
Sandra Jesse, Vice President Chief Legal Officer
Kent Davies, COO
Christopher Lindop, CFO and Executive VP of Bus. Devel.
Claire Pomeroy, Independent Director
Michelle Basil, Executive Vice President General Counsel
Christopher Simon, President, Chief Executive Officer, Director
Catherine Burzik, Independent Director
Mark Kroll, Independent Director
Dan Goldstein, Principal Accounting Officer
James Darecca, Executive Vice President, Chief Financial Officer
James CPA, Executive CFO
Jacqueline Scanlan, Senior Vice President - Human Resources
Josep Llorens, Senior Vice President - Global Manufacturing and Supply Chain
Farris Maunsell, Chief VP
Jonathan White, Chief Science and Technology Officer
Gerry Gould, IR Contact Officer
Jan MD, Senior Officer
Richard Meelia, Non-Executive Independent Chairman of the Board
Anila Lingamneni, Executive Vice President, Chief Technology Officer
Francis Tan, Sr Planning
Byron Selman, President - Global Markets
Charles Dockendorff, Independent Director
Thomas McCurdy, President - Global Plasma
Said Bolorforosh, Executive Vice President, Chief Technology Officer
Ronald Merriman, Independent Director
Pedro Granadillo, Independent Director
Lloyd Johnson, Director
Michael Coyle, Independent Director

Haemonetics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haemonetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stocks Directory
Find actively traded stocks across global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.05)
Earnings Share
2.46
Revenue Per Share
25.092
Quarterly Revenue Growth
0.101
Return On Assets
0.0612
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.